|
**Overview**: Follicle-Stimulating Hormone Luteinizing Hormone Panel**Introduction**: The Follicle-Stimulating Hormone Luteinizing Hormone Panel is a diagnostic tool designed to assess reproductive hormones using serum samples. In India, reproductive disorders (infertility, PCOS, hypogonadism, amenorrhea) affect ~15-20 percent of couples and women of reproductive age, with FSH/LH ratio abnormalities key in PCOS diagnosis (elevated LH/FSH) and primary/secondary hypogonadism differentiation. High morbidity from under-testing in rural/low-SES women with infertility or menstrual irregularities, limited endocrinology access, delayed clomiphene/IVF or hormone replacement leading to prolonged infertility or osteoporosis. Per endocrinology practices aligned with ICMR and FOGSI guidelines, the test employs immunoassay for FSH and LH over 1-2 days with high accuracy, valuable for ovulatory dysfunction workup and gonadal axis evaluation. This diagnostic falls under hormonal screening and targets women with infertility, irregular cycles, or men with hypogonadism, addressing accurate detection to guide ovulation induction or testosterone therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise hormonal assessment and reducing infertility burden. Its serum-based approach ensures reliable measurement.**Other Names**: FSH LH Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: FSH/LH ratio diagnostic; in India, used in infertility clinics.**Purpose**: The test assesses 2 parameters including FSH to guide reproductive hormone evaluation, detect axis disorders, inform therapy.**Test Parameters**: 1. FSH, 2. LH.**Pretest Condition**: No fasting required; patients should report menstrual issues or infertility.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cycle regularity, infertility duration, hirsutism.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated disorders including infertility, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or cycle phase can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal FSH/LH ratio indicates PCOS or hypogonadism, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Gynecologists or endocrinologists should be consulted for management.**Additional Supporting Tests**: AMH, ultrasound for confirmation.**Test Limitations**: Cycle-day dependent; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Infertility Studies India 2023. |
